Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Data by

Global Data

18

Revenue 2014

Astellas

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Astellas' 2013 sales performance.

Astellas extends phase III programme for Rydapt rival gilteritinib

Astellas extends phase III programme for Rydapt rival gilteritinib

Astellas extends phase III programme for Rydapt rival gilteritinib. Japanese group hopes its AML drug will soon compete with Novartis' recently-approved treatment. ... Astellas has started a fourth phase III trial of acute myeloid leukaemia (AML) drug

Ron Menezes joins Almirall’s Aqua Pharmaceuticals

Ron Menezes joins Almirall’s Aqua Pharmaceuticals Prior to his role at Depomed, Menezes was at Allergan in senior roles including vice president sales and marketing, medical dermatology and he has also held positions at Abbott, Astellas and

Bayer moves vilaprisan into phase III trials for uterine fibroids

Bayer moves vilaprisan into phase III trials for uterine fibroids Meanwhile, Allergan and Gedeon Richter plan to file their uterine fibroid drug ulipristal acetate in the US by the end of the year and Astellas is also busy in this area,

Sandoz HACk: It’s time to HACk Healthcare!

Action on Fistula - by Forster Communications for Astellas Pharma EMEA.

Basilea bags $72m upfront from Pfizer for antifungal license

Basilea bags $72m upfront from Pfizer for antifungal license In the US - where Cresemba is sold by Astellas - sales reached $46m, and analysts have predicted it could become a $500m-plus brand at peak. ... Astellas bought into the drug back in 2010 when it paid $86m up-front to Basilea, promising $550m more if the

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Global Data Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CACTUS

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

The_Pharma_Wars_Series.png
The Pharma Wars Series
The future galaxy is complex. Where markets are more competitive and customers more segmented, you’ve got to be smarter. But not only smarter, the Jedi today needs to be everywhere...
What pharma marketers can learn from growth hacking?
Growth hackers instinctively blend technical skills with creative thinking...
Medicines for Europe
The sound of silence puts the squeeze on generics and biosimilars
Medicines for Europe vows to get governments talking to realise potential...

Infographics